- Home
- PDS vs SEPN Comparison
PDS vs SEPN Comparison
Compare PDS & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDS
- SEPN
- Stock Information
- Founded
- PDS 1951
- SEPN 2022
- Country
- PDS Canada
- SEPN United States
- Employees
- PDS N/A
- SEPN N/A
- Industry
- PDS
- SEPN
- Sector
- PDS
- SEPN
- Exchange
- PDS Nasdaq
- SEPN NYSE
- Market Cap
- PDS 872.2M
- SEPN 1.0B
- IPO Year
- PDS N/A
- SEPN 2024
- Fundamental
- Price
- PDS $58.29
- SEPN $14.54
- Analyst Decision
- PDS Buy
- SEPN Strong Buy
- Analyst Count
- PDS 1
- SEPN 4
- Target Price
- PDS $95.00
- SEPN $43.67
- AVG Volume (30 Days)
- PDS 76.9K
- SEPN 212.8K
- Earning Date
- PDS 02-12-2025
- SEPN 02-15-2025
- Dividend Yield
- PDS N/A
- SEPN N/A
- EPS Growth
- PDS 62.11
- SEPN N/A
- EPS
- PDS 12.37
- SEPN N/A
- Revenue
- PDS $1,436,787,445.00
- SEPN $981,000.00
- Revenue This Year
- PDS $2.38
- SEPN $406.62
- Revenue Next Year
- PDS $2.42
- SEPN N/A
- P/E Ratio
- PDS $4.71
- SEPN N/A
- Revenue Growth
- PDS N/A
- SEPN N/A
- 52 Week Low
- PDS $54.49
- SEPN $13.97
- 52 Week High
- PDS $79.07
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- PDS 30.72
- SEPN N/A
- Support Level
- PDS $59.06
- SEPN N/A
- Resistance Level
- PDS $61.37
- SEPN N/A
- Average True Range (ATR)
- PDS 1.95
- SEPN 0.00
- MACD
- PDS -0.99
- SEPN 0.00
- Stochastic Oscillator
- PDS 8.09
- SEPN 0.00
About PDS Precision Drilling Corporation
Precision Drilling Corpd is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.